This angiocrine FGF4-FGFR1/Jag1-Notch2 loop contributed to extranodal invasion and chemoresistance, thus extending the clinical relevance of Jag1 targeting into lymphomas that lack Notch receptor mutations or JAG1 expression. Here, FGF4 is linked to lymphoma.